Blocking macrophage leukotriene B4 prevents endothelial injury and reverses pulmonary hypertension

Science Translational Medicine

Volumn 5, Issue 200, 2013, Pages

  Tian, Wen ^a   Jiang, Xinguo ^a   Tamosiuniene, Rasa ^a   Sung, Yon K ^a   Qian, Jin ^a   Dhillon, Gundeep ^b   Gera, Lajos ^c   Farkas, Laszlo ^d   Rabinovitch, Marlene ^b   Zamanian, Roham T ^b   Inayathullah, Mohammed ^b   Fridlib, Marina ^b   Rajadas, Jayakumar ^b   Peters Golden, Marc ^e   Voelkel, Norbert F ^d   Nicolls, Mark R ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLT1 PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; SPHINGOSINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLE; BIOSYNTHESIS; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HEART FUNCTION; HUMAN; HUMAN TISSUE; HYPERTROPHY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; EICOSANOIDS; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY; LEUKOTRIENE B4; MACROPHAGE ACTIVATION; MACROPHAGES; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PULMONARY ARTERY; RATS; SIGNAL TRANSDUCTION;

EID: 84883849935     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006674     Document Type: Review

References (84)

1. R. T. Schermuly, H. A. Ghofrani, M. R. Wilkins, F. Grimminger, Mechanisms of disease: Pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443-455 (2011).
2. M. R. Nicolls, L. Taraseviciene-Stewart, P. R. Rai, D. B. Badesch, N. F. Voelkel, Autoimmunity and pulmonary hypertension: A perspective. Eur. Respir. J. 26, 1110-1118 (2005).
3. P. M. Hassoun, L. Mouthon, J. A. Barberà, S. Eddahibi, S. C. Flores, F. Grimminger, P. L. Jones, M. L. Maitland, E. D. Michelakis, N. W. Morrell, J. H. Newman, M. Rabinovitch, R. Schermuly, K. R. Stenmark, N. F. Voelkel, J. X. Yuan, M. Humbert, Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54, S10-S19 (2009).
4. R. Tamosiuniene, W. Tian, G. Dhillon, L. Wang, Y. K. Sung, L. Gera, A. J. Patterson, R. Agrawal, M. Rabinovitch, K. Ambler, C. S. Long, N. F. Voelkel, M. R. Nicolls, Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ. Res. 109, 867-879 (2011).
5. R. M. Tuder, N. F. Voelkel, Pulmonary hypertension and inflammation. J. Lab. Clin. Med. 132, 16-24 (1998).
6. P. Dorfmüller, F. Perros, K. Balabanian, M. Humbert, Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22, 358-363 (2003).
7. L. Taraseviciene-Stewart, M. R. Nicolls, D. Kraskauskas, R. Scerbavicius, N. Burns, C. Cool, K. Wood, J. E. Parr, S. A. Boackle, N. F. Voelkel, Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am. J. Respir. Crit. Care Med. 175, 1280-1289 (2007).
8. M. Peters-Golden, W. R. Henderson Jr., Leukotrienes. N. Engl. J. Med. 357, 1841-1854 (2007).
9. M. Peters-Golden, T. G. Brock, 5-Lipoxygenase and FLAP. Prostaglandins Leukot. Essent. Fatty Acids 69, 99-109 (2003).
10. O. Werz, J. Klemm, B. Samuelsson, O. Rådmark, 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc. Natl. Acad. Sci. U.S.A. 97, 5261-5266 (2000).
11. O. Werz, D. Szellas, D. Steinhilber, O. Rådmark, Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J. Biol. Chem. 277, 14793-14800 (2002).
12. O. Rådmark, B. Samuelsson, Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis. Biochem. Biophys. Res. Commun. 396, 105-110 (2010).
13. 4 synthetic capacity. Proc. Natl. Acad. Sci. U.S.A. 100, 12165-12170 (2003).
14. N. Flamand, M. Luo, M. Peters-Golden, T. G. Brock, Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J. Biol. Chem. 284, 306-313 (2009).
15. L. Wright, R. M. Tuder, J. Wang, C. D. Cool, R. A. Lepley, N. F. Voelkel, 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 157, 219-229 (1998).
16. N. F. Voelkel, R. M. Tuder, K. Wade, M. Höper, R. A. Lepley, J. L. Goulet, B. H. Koller, F. Fitzpatrick, Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J. Clin. Invest. 97, 2491-2498 (1996).
17. Y. Song, J. E. Jones, H. Beppu, J. F. Keaney Jr., J. Loscalzo, Y. Y. Zhang, Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112, 553-562 (2005).
18. 4 in neonates with hypoxemia and pulmonary hypertension. N. Engl. J. Med. 309, 77-80 (1983).
19. 4 on the microvasculature of guinea-pig skin. Prostaglandins 21, 315-321 (1981).
20. L. Taraseviciene-Stewart, Y. Kasahara, L. Alger, P. Hirth, G. McMahon, J. Waltenberger, N. F. Voelkel, R. M. Tuder, Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427-438 (2001).
21. N. R. Bauer, T. M. Moore, I. F. McMurtry, Rodent models of PAH: Are we there yet? Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L580-L582 (2007).
22. M. S. Balter, W. L. Eschenbacher, M. Peters-Golden, Arachidonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am. Rev. Respir. Dis. 138, 1134-1142 (1988).
23. M. J. Coffey, S. M. Phare, M. Peters-Golden, G. B. Huffnagle, Regulation of 5-lipoxygenase metabolism in mononuclear phagocytes by CD4 T lymphocytes. Exp. Lung Res. 25, 617-629 (1999).
24. M. Peters-Golden, R. W. McNish, R. Hyzy, C. Shelly, G. B. Toews, Alterations in the pattern of arachidonate metabolism accompany rat macrophage differentiation in the lung. J. Immunol. 144, 263-270 (1990).
25. A. Sindrilaru, T. Peters, S. Wieschalka, C. Baican, A. Baican, H. Peter, A. Hainzl, S. Schatz, Y. Qi, A. Schlecht, J. M. Weiss, M. Wlaschek, C. Sunderkötter, K. Scharffetter-Kochanek, An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J. Clin. Invest. 121, 985-997 (2011).
26. P. G. Holt, A. Degebrodt, T. Venaille, C. O'Leary, K. Krska, J. Flexman, H. Farrell, G. Shellam, P. Young, J. Penhale, T. Robertson, J. M. Papadimitriou, Preparation of interstitial lung cells by enzymatic digestion of tissue slices: Preliminary characterization by morphology and performance in functional assays. Immunology 54, 139-147 (1985).
27. G. Franke-Ullmann, C. Pförtner, P. Walter, C. Steinmüller, M. L. Lohmann-Matthes, L. Kobzik, Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. J. Immunol. 157, 3097-3104 (1996).
28. G. Bonizzi, J. Piette, S. Schoonbroodt, R. Greimers, L. Havard, M. P. Merville, V. Bours, Reactive oxygen intermediate-dependent NF-κB activation by interleukin-1β requires 5-lipoxygenase or NADPH oxidase activity. Mol. Cell. Biol. 19, 1950-1960 (1999).
29. 1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 102, 17501-17506 (2005).
30. C. Rodríguez, M. González-Díez, L. Badimon, J. Martínez-González, Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost. 101, 665-673 (2009).
31. S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, A. M. Zeiher, Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999).
32. 4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. J. Biol. Chem. 266, 1375-1378 (1991).
33. 4 hydrolase. Biochem. Pharmacol. 48, 131-137 (1994).
34. O. A. Scornik, V. Botbol, Bestatin as an experimental tool in mammals. Curr. Drug Metab. 2, 67-85 (2001).
35. 4 hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. Am. J. Respir. Crit. Care Med. 181, 899-907 (2010).
36. M. Miyata, F. Sakuma, M. Ito, H. Ohira, Y. Sato, R. Kasukawa, Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int. Arch. Allergy Immunol. 121, 246-252 (2000).
37. R. Speich, R. Jenni, M. Opravil, M. Pfab, E. W. Russi, Primary pulmonary hypertension in HIV infection. Chest 100, 1268-1271 (1991).
38. + T cells in patients with systemic lupus erythematosus. J. Immunol. 182, 1689-1695 (2009).
39. T. R. Radstake, L. van Bon, J. Broen, M. Wenink, K. Santegoets, Y. Deng, A. Hussaini, R. Simms, W. W. Cruikshank, R. Lafyatis, Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS One 4, e5981 (2009).
40. M. I. Covas, A. Esquerda, A. García-Rico, N. Mahy, Peripheral blood T-lymphocyte subsets in autoimmune thyroid disease. J. Investig. Allergol. Clin. Immunol. 2, 131-135 (1992).
41. T. Mandl, A. Bredberg, L. T. Jacobsson, R. Manthorpe, G. Henriksson, CD4+ T-lymphocytopenia-A frequent finding in anti-SSA antibody seropositive patients with primary Sjögren's syndrome. J. Rheumatol. 31, 726-728 (2004).
42. T. Papo, J. C. Piette, E. Legac, C. Frances, P. Grenot, P. Debre, P. Godeau, B. Autran, T lymphocyte subsets in primary antiphospholipid syndrome. J. Rheumatol. 21, 2242-2245 (1994).
43. J. Y. Jeremy, D. Rowe, A. M. Emsley, A. C. Newby, Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc. Res. 43, 580-594 (1999).
44. Y. Xia, J. L. Zweier, Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U.S.A. 94, 6954-6958 (1997).
45. R. A. Lang, J. M. Bishop, Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell 74, 453-462 (1993).
46. S. Sugiyama, K. Kugiyama, M. Aikawa, S. Nakamura, H. Ogawa, P. Libby, Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 1309-1314 (2004).
47. E. Vergadi, M. S. Chang, C. Lee, O. D. Liang, X. Liu, A. Fernandez-Gonzalez, S. A. Mitsialis, S. Kourembanas, Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation 123, 1986-1995 (2011).
48. T. Thenappan, A. Goel, G. Marsboom, Y. H. Fang, P. T. Toth, H. J. Zhang, H. Kajimoto, Z. Hong, J. Paul, C. Wietholt, J. Pogoriler, L. Piao, J. Rehman, S. L. Archer, A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am. J. Respir. Crit. Care Med. 183, 1080-1091 (2011).
49. J. Björk, P. Hedqvist, K. E. Arfors, Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation 6, 189-200 (1982).
50. A. Di Gennaro, E. Kenne, M. Wan, O. Soehnlein, L. Lindbom, J. Z. Haeggström, Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin) . FASEB J. 23, 1750-1757 (2009).
51. H. Qiu, A. Gabrielsen, H. E. Agardh, M. Wan, A. Wetterholm, C. H. Wong, U. Hedin, J. Swedenborg, G. K. Hansson, B. Samuelsson, G. Paulsson-Berne, J. Z. Haeggström, Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. U.S.A. 103, 8161-8166 (2006).
52. C. E. Chalfant, S. Spiegel, Sphingosine 1-phosphate and ceramide 1-phosphate: Expanding roles in cell signaling. J. Cell Sci. 118, 4605-4612 (2005).
53. L. Wang, S. M. Dudek, Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc. Res. 77, 39-45 (2009).
54. E. D. Michelakis, M. S. McMurtry, X. C. Wu, J. R. Dyck, R. Moudgil, T. A. Hopkins, G. D. Lopaschuk, L. Puttagunta, R. Waite, S. L. Archer, Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 105, 244-250 (2002).
55. M. S. McMurtry, S. Bonnet, X. Wu, J. R. Dyck, A. Haromy, K. Hashimoto, E. D. Michelakis, Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 95, 830-840 (2004).
56. M. S. McMurtry, S. L. Archer, D. C. Altieri, S. Bonnet, A. Haromy, G. Harry, L. Puttagunta, E. D. Michelakis, Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115, 1479-1491 (2005).
57. S. L. Merklinger, P. L. Jones, E. C. Martinez, M. Rabinovitch, Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112, 423-431 (2005).
58. Q. Yang, Z. Lu, R. Ramchandran, L. D. Longo, J. U. Raj, Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: Role of histone acetylation. Am. J. Physiol. Lung Cell. Mol. Physiol. 303, L1001-L1010 (2012).
59. J. Wang, Q. Jiang, L. Wan, K. Yang, Y. Zhang, Y. Chen, E. Wang, N. Lai, L. Zhao, H. Jiang, Y. Sun, N. Zhong, P. Ran, W. Lu, Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am. J. Respir. Cell Mol. Biol. 48, 125-134 (2013).
60. E. A. Heller, E. Liu, A. M. Tager, S. Sinha, J. D. Roberts, S. L. Koehn, P. Libby, E. R. Aikawa, J. Q. Chen, P. Huang, M. W. Freeman, K. J. Moore, A. D. Luster, R. E. Gerszten, Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112, 578-586 (2005).
61. T. P. Alastalo, M. Li, J. Perez Vde, D. Pham, H. Sawada, J. K. Wang, M. Koskenvuo, L. Wang, B. A. Freeman, H. Y. Chang, M. Rabinovitch, Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J. Clin. Invest. 121, 3735-3746 (2011).
62. V. A. Perez, Z. Ali, T. P. Alastalo, F. Ikeno, H. Sawada, Y. J. Lai, T. Kleisli, E. Spiekerkoetter, X. Qu, L. H. Rubinos, E. Ashley, M. Amieva, S. Dedhar, M. Rabinovitch, BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. J. Cell Biol. 192, 171-188 (2011).
63. T. Tabata, S. Ono, C. Song, M. Noda, S. Suzuki, T. Tanita, S. Fujimura, Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension. Nihon Kyobu Shikkan Gakkai Zasshi 35, 160-166 (1997).
64. K. Sekine, H. Fujii, F. Abe, Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 13, 729-734 (1999).
65. 4 synthesized by polymorphonuclear leukocytes. J. Biol. Chem. 261, 16466-16472 (1986).
66. 4 in conscious rabbits. Br. J. Pharmacol. 112, 654-658 (1994).
67. R. Bowers, C. Cool, R. C. Murphy, R. M. Tuder, M. W. Hopken, S. C. Flores, N. F. Voelkel, Oxidative stress in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 169, 764-769 (2004).
68. A. Alunno, E. Bartoloni, O. Bistoni, G. Nocentini, S. Ronchetti, S. Caterbi, V. Valentini, C. Riccardi, R. Gerli, Balance between regulatory T and Th17 cells in systemic lupus erythematosus: The old and the new. Clin. Dev. Immunol. 2012, 823085 (2012).
69. J. Orme, C. Mohan, Macrophage subpopulations in systemic lupus erythematosus. Discov. Med. 13, 151-158 (2012).
70. N. Higashi-Kuwata, M. Jinnin, T. Makino, S. Fukushima, Y. Inoue, F. C. Muchemwa, Y. Yonemura, Y. Komohara, M. Takeya, H. Mitsuya, H. Ihn, Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res. Ther. 12, R128 (2010).
71. R. Savai, S. S. Pullamsetti, J. Kolbe, E. Bieniek, R. Voswinckel, L. Fink, A. Scheed, C. Ritter, B. K. Dahal, A. Vater, S. Klussmann, H. A. Ghofrani, N. Weissmann, W. Klepetko, G. A. Banat, W. Seeger, F. Grimminger, R. T. Schermuly, Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 897-908 (2012).
72. N. Kherbeck, M. C. Tamby, G. Bussone, H. Dib, F. Perros, M. Humbert, L. Mouthon, The Role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin. Rev. Allergy Immunol. 44, 31-38 (2013).
73. A. Huertas, L. Tu, N. Gambaryan, B. Girerd, F. Perros, D. Montani, D. Fabre, E. Fadel, S. Eddahibi, S. Cohen-Kaminsky, C. Guignabert, M. Humbert, Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 40, 895-904 (2012).
74. R. Sun, X. Ba, L. Cui, Y. Xue, X. Zeng, Leukotriene B4 regulates proliferation and differentiation of cultured rat myoblasts via the BLT1 pathway. Mol. Cells 27, 403-408 (2009).
75. B. D. Levy, G. T. De Sanctis, P. R. Devchand, E. Kim, K. Ackerman, B. A. Schmidt, W. Szczeklik, J. M. Drazen, C. N. Serhan, Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med. 8, 1018-1023 (2002).
76. X. Chen, S. Wang, N. Wu, C. S. Yang, Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr. Cancer Drug Targets 4, 267-283 (2004).
77. S. D. Lee, K. R. Shroyer, N. E. Markham, C. D. Cool, N. F. Voelkel, R. M. Tuder, Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J. Clin. Invest. 101, 927-934 (1998).
78. P. R. Rai, C. D. Cool, J. A. King, T. Stevens, N. Burns, R. A. Winn, M. Kasper, N. F. Voelkel, The cancer paradigm of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 558-564 (2008).
79. P. Mancuso, C. Lewis, C. H. Serezani, D. Goel, M. Peters-Golden, Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia. Infect. Immun. 78, 2264-2271 (2010).
80. K. Ota, S. Kurita, K. Yamada, T. Masaoka, Y. Uzuka, N. Ogawa, Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol. Immunother. 23, 5-10 (1986).
81. Y. Ichinose, K. Genka, T. Koike, H. Kato, Y. Watanabe, T. Mori, S. Iioka, A. Sakuma, M. Ohta; NK421 Lung Cancer Surgery Group, Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J. Natl. Cancer Inst. 95, 605-610 (2003).
82. L. A. Dethloff, B. E. Lehnert, Pulmonary interstitial macrophages: Isolation and flow cytometric comparisons with alveolar macrophages and blood monocytes. J. Leukoc. Biol. 43, 80-90 (1988).
83. H. Beppu, F. Ichinose, N. Kawai, R. C. Jones, P. B. Yu, W. M. Zapol, K. Miyazono, E. Li, K. D. Bloch, BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L1241-L1247 (2004).
84. 4 prevents endothelial injury and reverses pulmonary hypertension. Sci. Transl. Med. 5, 200ra117 (2013).